Hemogenyx Pharmaceuticals (LSE:HEMO) reported that holders have exercised warrants resulting in the issuance of 67,371 new ordinary shares. The transaction has raised approximately £235,799 in subscription proceeds.
The newly issued shares will be admitted to trading on the London Stock Exchange, bringing the company’s total issued share capital to 5,361,267. Investors are advised to use this updated figure when calculating their percentage holdings in the company.
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a London-based, publicly listed clinical-stage biopharmaceutical company with subsidiaries in New York. The firm is dedicated to developing innovative therapies for blood and autoimmune disorders, leveraging a pipeline of product candidates and proprietary platform technologies to advance novel treatments.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply